Becton Dickinson and Co (NYSE:BDX) – Analysts at Leerink Swann issued their Q1 2019 earnings per share estimates for shares of Becton Dickinson and in a research note issued to investors on Wednesday, November 7th. Leerink Swann analyst R. Newitter forecasts that the medical instruments supplier will post earnings per share of $2.65 for the quarter. Leerink Swann also issued estimates for Becton Dickinson and’s Q2 2019 earnings at $2.86 EPS, Q3 2019 earnings at $3.27 EPS and Q4 2019 earnings at $3.31 EPS.
A number of other research firms have also recently issued reports on BDX. Wells Fargo & Co decreased their target price on Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday. Barclays set a $260.00 price target on Becton Dickinson and and gave the company a “hold” rating in a report on Thursday. Morgan Stanley boosted their price target on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. KeyCorp restated a “buy” rating and issued a $264.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, Citigroup boosted their price target on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and an average price target of $254.07.
Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.93. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the firm earned $2.40 earnings per share. The company’s revenue was up 39.0% on a year-over-year basis.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in Becton Dickinson and by 1.3% during the third quarter. BlackRock Inc. now owns 19,029,060 shares of the medical instruments supplier’s stock worth $4,966,582,000 after acquiring an additional 253,041 shares in the last quarter. FMR LLC raised its holdings in Becton Dickinson and by 8.0% during the third quarter. FMR LLC now owns 17,354,031 shares of the medical instruments supplier’s stock worth $4,529,401,000 after acquiring an additional 1,286,579 shares in the last quarter. Fundsmith Equity Fund L.P. bought a new stake in Becton Dickinson and during the second quarter worth about $894,775,000. Wells Fargo & Company MN raised its holdings in Becton Dickinson and by 0.8% during the third quarter. Wells Fargo & Company MN now owns 3,565,101 shares of the medical instruments supplier’s stock worth $930,491,000 after acquiring an additional 27,188 shares in the last quarter. Finally, Putnam Investments LLC raised its holdings in Becton Dickinson and by 0.5% during the second quarter. Putnam Investments LLC now owns 3,513,485 shares of the medical instruments supplier’s stock worth $841,690,000 after acquiring an additional 18,859 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.
In related news, EVP James C. Lim sold 5,189 shares of the company’s stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the sale, the executive vice president now owns 13,318 shares in the company, valued at $3,227,750.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Timothy M. Ring sold 42,000 shares of the company’s stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total value of $9,956,940.00. Following the sale, the director now owns 93,688 shares in the company, valued at approximately $22,210,614.16. The disclosure for this sale can be found here. Insiders own 1.00% of the company’s stock.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Read More: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.